US 12,473,328 B2
Method for modification of peptides immobilized on a solid support by traceless reductively cleavable linker molecules
Robert Zitterbart, Berlin (DE); and Oliver Reimann, Berlin (DE)
Assigned to BELYNTIC GMBH, Berlin (DE)
Appl. No. 17/633,200
Filed by BELYNTIC GMBH, Berlin (DE)
PCT Filed Aug. 7, 2020, PCT No. PCT/EP2020/072330
§ 371(c)(1), (2) Date Feb. 6, 2022,
PCT Pub. No. WO2021/023892, PCT Pub. Date Feb. 11, 2021.
Claims priority of application No. 19190627 (EP), filed on Aug. 7, 2019.
Prior Publication US 2022/0363713 A1, Nov. 17, 2022
Int. Cl. C07K 1/107 (2006.01); A61K 38/26 (2006.01); C07K 17/10 (2006.01)
CPC C07K 1/1075 (2013.01) [A61K 38/26 (2013.01); C07K 17/10 (2013.01)] 15 Claims
 
1. A method for modifying and purifying peptides comprising the steps of
providing a crude linker-tagged peptide L-P, wherein the crude peptide P is covalently bound to a linker molecule L;
immobilizing L-P by coupling L-P to a solid support S yielding an immobilized S-L-P;
modifying S-L-P by introducing a modification into S-L-P yielding an immobilized S-L-mP;
wherein mP is a modified peptide and the modification is selected from the group consisting of lipidation and cyclization; wherein lipidation comprises a compound selected from the group consisting of formula FAx-Spn-A (5a), FAx-Spn-OH (5b), FA-A (5c), and FA-OH (5d); wherein
FA is a —C(═O)—C1-24-alkyl or a —C(═O)—C2-24-alkenyl, wherein the alkyl or the alkenyl moiety may be unsubstituted or substituted by one or more substituents independently selected from —F and —COOH;
Sp is a spacer 2 to 50 atoms in length and x linking moieties independently selected from the group consisting of —NH—, —O—, —S—, wherein the spacer is connected to FA via the linking moiety;
x is an integer between 1 and 5;
n is an integer between 1 and 10;
A is selected from the group consisting of —F, —Cl, —Br, —I, —N3, —O(C═O)CH2(C═O)OH, —SR14, —OCF3, —OCH2CF3, —OSO2CF3, —SO2C6H4CH3, —SO2CF3, and —SO2CH3,

OG Complex Work Unit Chemistry
wherein R14 is selected from the group consisting of C1-C6-alkyl-, an arylic- and benzylic substituent;
wherein cyclization comprises disulfide formation; and wherein intramolecular or intermolecular cyclization by using an organic scaffold molecule, wherein the peptide comprises at least two amino acids comprising a nucleophilic thiol for intramolecular cyclization by disulfide formation or for intermolecular cyclization using an organic scaffold molecule having at least two electrophilic centers; wherein the electrophilic center is formed by halogen substituents and/or Michael acceptors, and is formed by at least two benzylic halogen substituents, at least two acrylamides or at least two acryl esters;
wherein the organic scaffold molecule is selected from the group consisting of 1,4-Bis(bromomethyl)benzene, m-Xylylene dibromide (mDBX), 1,3,5-Tris(bromomethyl) benzene (TBMB), N,N′-bis(chloroacetyl)-1,2-ethylenediamine, N,N′-bis(chloroacetyl)-1,3-propylenediamine, N,N′-((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(2-chloroacetamide), N,N′-bis(bromoacetyl)-1,2-ethylenediamine, N,N′-bis(bromoacetyl)-1,3-propylenediamine, N,N′-((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(2-bromoacetamide), 1,3,5-Triacryloyl-1,3,5-triazinan (TATA), 1,1′,1″-(1,3,5-Triazinan-1,3,5-triyl)tris(2-bromoethanon) (TATB), N,N′,N″-(benzene-1,3,5-triyl)-tris(2-bromoacetamide) (TBAB), N,N′,N″-benzene-1,3,5-triyltrisprop-2-enamide (TAAB), 2,4,6-tris(bromomethyl)-s-triazine (TBMT), N,N′,N″-(Nitrilotris(ethane-2,1-diyl))triacrylamide, N,N′,N″-(Nitrilotris(ethane-2,1-diyl))tris(2-chloroacetamide), N,N′,N″-(Nitrilotris(ethane-2,1-diyl))tris(2-bromoacetamide), N,N′,N″-(Nitrilotris(ethane-2,1-diyl))triethenesulfonamide, N,N′,N″-((1,3,5-Triazinane-1,3,5-triyl)tris(2-oxoethane-2,1-diyl))triacrylamide, N,N′,N″-((1,3,5-Triazinane-1,3,5-triyl)tris(2-oxoethane-2,1-diyl))tris(2-chloroacetamide), N,N′,N″-((1,3,5-Triazinane-1,3,5-triyl)tris(2-oxoethane-2,1-diyl))triethenesulfonamide, N,N′,N″-(Benzene-1,3,5-triyltris(methylene))triacrylamide, N,N′,N″-(Benzene-1,3,5-triyltris(methylene))tris(2-chloroacetamide), N,N′,N″-(Benzene-1,3,5-triyltris(methylene))triethenesulfonamid, Tri(2-hydroxyethyl)isocyanurate triacrylate, 1,3,5-Tris(oxiran-2-ylmethyl)-1,3,5-triazinane-2,4,6-trione;
reducing RI by adding a reducing agent yielding a reduced intermediate RI to yield mP;
wherein L is a compound of formula 1 comprising X-Tb-Va-U—Y; wherein
a. X is selected from the group consisting of 2, 2a, 3, 3a and 4,

OG Complex Work Unit Chemistry
 wherein
i. each R1 and R2 is independently from each other selected from the group consisting of H and B; wherein at least one of R1 or R2 is B;
ii. R3 is selected from the group consisting of H and B;
iii. R4 is H, C1-C12-alkyl or aryl, wherein the aldehyde or keto group is selected from the group consisting of an unprotected aldehyde or keto group and a protected aldehyde or keto group; wherein the protecting group is an acid labile protecting group;
iv. B is an acid labile amine protecting group;
b. Tb is a linear or branched spacer with b being 0 or 1;
c. Va is an electron-withdrawing moiety with a being 0 or 1, wherein the sum of a and b is 1 or 2;
d. U is a phenyl or a five- or six-membered heteroaryl moiety, that is bound to at least one moiety selected from the group consisting of V, Wq and Ej; wherein
i. Wq is selected from the group consisting of —N3, —NO2, —S(═O)—R8, —S—S—R8, —O—CH2—N3, —O—C(═O)—O—CH2—N3, —N═N-phenyl, —N═N— and R8,

OG Complex Work Unit Chemistry
 wherein
R8 is selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyridazyl, —C1-C6-alkyl and —(CH2)p—NMe2, with q being 1, 2, 3 or 4; wherein Wq is in ortho or para position in relation to Y;
ii. Ej is an electron withdrawing group and j is selected from the group consisting of 0, 1, 2, 3 and 4;
wherein when U is a phenyl moiety and Y is —(CH2)m—O—C(═O)—, the sum of Hammett constants of V, Wq, Ej under acidic conditions is larger than 0.45; and
e. Y is —(CH2)m—C(═O)— or —(CH2)m—O—C(═O)— with m being 1, 2 or 3.